IL-23p40 specific antibody

• US 7,247,711 B2
• Filed: 05/06/2004
• Issued: 07/24/2007
• Est. Priority Date: 05/09/2003
• Status: Active Grant

• Current Assignee: Centocor Incorporated (Johnson & Johnson)
• Original Assignee: Centocor Incorporated (Johnson & Johnson)
• Inventors: Cunningham, Mark, Benson, Jacqueline
• Primary Examiner(s): Landsman; Robert S.
• Assistant Examiner(s): Hissong; Bruce D.
• Application Number:
  US10/840,789
• Publication Number:
  US 20050137385A1
• Time in Patent Office: 1,174 Days
• Field of Search: None
• US Class Current: 530/388.23
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/244 Interleukins [IL]
• CPC Class Codes: C07K 2317/74 Inducing cell proliferation
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Novel anti-IL-23p40 specific human Ig derived proteins, including, without limitation, antibodies, fusion proteins, and mimetibodies, isolated nucleic acids that encode the anti-IL-23p40 Ig derived proteins, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, are useful for therapeutic compositions, methods and devices. Preferably, the anti-IL-23p40 specific human Ig derived proteins do not bind the p40 subunit of IL-12 and, thus, do not neutralize IL-12-related activity.

Claims

1. An isolated anti-interleukin (IL)-23p40 antibody, wherein said antibody specifically binds to a region comprising amino acids 138-145 of SEQ ID NO:

1, wherein said antibody binds the p40 subunit of the IL-23 protein and wherein said antibody does not bind the p40 subunit of the IL-12 protein.

2. The isolated anti-IL-23p40 antibody according to claim 1, wherein said antibody inhibits IL-23 activity in at least one of an antigen presenting cell (APC), lymphocyte, and autoreactive T cell.

3. The isolated anti-IL-23p40 antibody according to claim 2, wherein said APC or lymphocyte is in a tissue within the central nervous system.

4. The isolated anti-IL-23p40 antibody according to claim 2, wherein said APC or lymphocyte is in a tissue outside the central nervous system.

5. The isolated anti-IL-23p40 antibody according to claim 2, wherein said APC is selected from at least one of a macrophage, microglia, Langerhans cell, Kuppfer cell, dendritic cell, B cell, alveolar macrophage, blood monocyte, and synovial A cell.

6. The anti-IL-23p40 antibody according to claim 1, wherein said antibody neutralizes at least one activity of an IL-23 protein.

7. A composition comprising the anti-IL-23p40 antibody according to claim 1 and at least one pharmaceutically acceptable carrier or diluent.

8. The composition according to claim 7, further comprising an effective amount of at least one compound or protein selected from at least one of a detectable label or reporter, an immune therapeutic, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplastic, an immunomodulation drug, an opthalmic, otic or nasal drug, a topical drug, a TNF antagonist, an antirheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteriod, an anabolic steroid, an erythropoietin, a vaccine, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an antidepressant, an antipsychotic, a stimulant, an asthma medication, a beta agonist, an inhaled steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.

9. The anti-IL-23p40 antibody of claim 1 produced in an appropriate host cell, transgenic animal, transgenic plant, or plant cell capable of expressing recoverable amounts of the antibody.